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Background: International travel contributes to the worldwide spread of multidrug resistant Gram-negative bacteria.
Rates of travel-related faecal colonization with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae
vary for different destinations. Especially travellers returning from the Indian subcontinent show high colonization rates.
So far, nothing is known about region-specific risk factors for becoming colonized.
Methods: An observational prospective multicentre cohort study investigated travellers to South Asia. Before and after
travelling, rectal swabs were screened for third-generation cephalosporin- and carbapenem-resistant Enterobacteriaceae.
Participants completed questionnaires to identify risk factors for becoming colonized. Covariates were assessed
univariately, followed by a multivariate regression.
Results: Hundred and seventy persons were enrolled, the largest data set on travellers to the Indian subcontinent so
far. The acquired colonization rate with ESBL-producing Escherichia coli overall was 69.4% (95% CI 62.1-75.9%), being
highest in travellers returning from India (86.8%; 95% CI 78.5-95.0%) and lowest in travellers returning from Sri Lanka
(34.7%; 95% CI 22.9-48.7%). Associated risk factors were travel destination, length of stay, visiting friends and relatives,
and eating ice cream and pastry.
Conclusions: High colonization rates with ESBL-producing Enterobacteriaceae were found in travellers returning from
South Asia. Though risk factors were identified, a more common source, i.e. environmental, appears to better explain
the high colonization rates.
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According to the Global Report on Surveillance of anti-
microbial resistance of the World Health Organization
(WHO), resistance rates to third-generation cephalospo-
rins of up to 50-80% have been described for all WHO
regions. This increase in multidrug-resistance is not only
associated with increased morbidity and mortality and
higher cost, but with the need to use broader spectrum
antibiotics to treat common infections, therefore further
facilitating resistance development [1,2].
Originally, multidrug-resistant (MDR) Gram-negative
bacteria were considered to occur mainly in healthcare
settings. However, since the late 1990s, the importance
of ESBL-producing Escherichia coli (ESBL-Ec) as a major
cause for community-acquired infections has become
evident. Recent analyses showed that up to 70% of infec-
tions due to ESBL-Ec are community-acquired [3,4].
The reasons for this increase in infections caused by
ESBL-Ec are manifold, including: the ”classical“ risk
factors such as previous antibiotic use (cephalosporins
and fluoroquinolones), age, and the presence of co-
morbidities [2]. Moreover, animals, food, and the envir-
onment serve as reservoirs for MDR Gram-negative
bacteria [5]. While the evidence for direct animal-to-
human transmission of MDR bacteria or their respective
mobile genetic resistance traits is mainly circumstantial
[5], more robust evidence for transmission via the food
chain exists [6,7]. Furthermore, investigations in re-
cent years have shown international travel as a possible
means of spreading ESBL-producing Enterobacteriaceae
(ESBL-Ent), mainly ESBL-Ec, from high- to low-prevalence
countries through asymptomatic travellers [8-13], thereby
increasing the local prevalence and changing the local
epidemiology with the import of non-autochthonous
ESBL-Ent [14].
The impact of travelling on the local epidemiology of
ESBL-Ent might be considerable, due to intense inter-
national travel [15] and very high colonization rates
associated with some travel destinations [8,9,11-13]. An
even greater threat, though occurring to a much lesser
extent so far, is the spread of carbapenemase-producing
Enterobacteriaceae (Carb-Ent), such as NDM and OXA-
48-like-producers [16,17].
Several studies have tried to identify risk factors for
becoming colonized while travelling [8,9,11-13,18-20].
However, besides region visited, and, to some extent,
suffering from gastrointestinal symptoms while travel-
ling, the findings varied between the studies. As all these
surveys looked at multiple travel destinations, this could
be explained by risk factors varying among different
regions of the world. Otherwise, especially in highly-
endemic areas (like India) [21], ESBL-Ec could occur in
such abundance in the environment that their acquisi-
tion no longer depends on singular risk factors.The primary aim of this study was to investigate
colonization rates in travellers returning from South
Asia, a travel destination known to be associated with
high colonization rates [8,9,11-13]. By focusing on one
region of the world, the question of region-dependent
risk factors for becoming colonized could be addressed.
Moreover, more information on the regional distribution
of different E. coli isolates was collected. Most impor-
tantly, the knowledge about the mechanism behind
becoming colonized with ESBL-Ec in South Asia may
be extrapolated to Carb-Ent, thereby helping to contain
their spread.
Methods
Study population
Between December 2012 and October 2013, healthy
travellers who planned to travel to South Asia (India,
Bhutan, Nepal and Sri Lanka) and received pre-travel
advice at the two largest Travel Clinics of German-
speaking Switzerland, were enrolled in the study. There
was no age restriction for inclusion in the study. Clients
travelling for more than five weeks, travelling to other
countries than India, Bhutan, Nepal, and Sri Lanka or to
more than one of these countries, were excluded from
participation. The study was approved by the local ethics
committees (Ethikkommission beider Basel (Nr. 239/12),
Kantonale Ethikkommission Zürich (Nr. 2013–0066). All
participants gave written informed consent. A parent or
a legal guardian had to sign the informed consent on be-
half of minors.
Collection of samples
Faecal samples were collected through self-applied rectal
swabs (M40 Transystem, Copan Italia, Brescia, Italy) in
the week before and directly after travelling and then
sent by mail to the Division of Clinical Microbiology,
University Hospital Basel. Oral and written explanations
of how to use the swabs were provided for all partici-
pants. On each occasion, a questionnaire assessing risk
factors for becoming or remaining colonized was com-
pleted. The questionnaire was paper-based and consisted
of multiple choice or one-word answers.
Microbiological analysis
Faecal samples were cultured overnight at 37°C in trypti-
case soy broth with 0.5% sodium chloride [22], followed
by inoculation of a selective chromogenic medium for the
detection of third-generation cephalosporin resistant
organisms (chromID® ESBL, bioMérieux, Marcy-l’Etoile,
France) and a MacConkey agar (Becton Dickinson, Breda,
The Netherlands) with an ertapenem disk. Colonies gro-
wing on the chromogenic agar plate and within the erta-
penem disk zone were identified using Vitek-2® system
(bioMérieux, Hazelwood, Mo, USA). The Vitek-2® system
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interpreted according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) [23].
Cefoxitin was used to screen for acquired AmpC-production.
Minimum inhibitory concentration (MIC) values for se-
veral antibiotics including meropenem and ertapenem
were determined by Etest® (bioMérieux). To phenotypic-
ally detect ESBL, AmpC and carbapenemase production,
we performed various combination disk tests (ROSCO
Neosensitabs, Rosco Diagnostica, Taastrup Denkmark)
and the modified Hodge test according to Clinical and
Laboratory Standards Institute (CLSI) guidelines. The
ROSCO Neo-Sensitabs were used according to the manu-
facturer’s recommendations and Hansen et al. [24].
Molecular characterization of isolates
Eighty randomly selected E. coli isolates resistant to third-
generation cephalosporins or those possessing a phenotype
suggestive of ESBL production were screened using the
CT-104 microarray (Check-Points, PD Wageningen, The
Netherlands) to screen for the presence of class A (blaTEM,
blaSHV, blaCTX-M, blaKPC), class B (blaNDM, blaVIM, blaIMP),
class C plasmid-mediated AmpCs (pAmpCs) (blaCMY,
blaFOX, blaDHA, blaMOX, blaACC, blaACT), and class D
(blaOXA-48-like) β-lactamase genes. Genomic extraction was
performed using the QIAmp DNA mini kit (QIAGEN).
PCR/DNA sequence analyses for the bla genes (i.e., blaSHV
and blaCTX-M) found with the microarray were performed
using primers and conditions previously reported [4,17].
Sequences were analysed using DNAStar (Lasergene),
translated into protein sequences (ExPASy; http://ch.
expasy.org/), and compared to those previously described
(http://www.lahey.org/Studies).
Analysis of clonal relatedness
The relatedness of the 80 representative E. coli isolates was
analysed by repetitive extragenic palindromic polymerase
chain reaction (rep-PCR) as previously described. Isolates
were defined as clonally-related when they had >85%
genetic relatedness [25]. Multi locus sequence typing
(MLST) was also performed for a randomly selected sub-
group of 34 isolates according to the Achtman scheme
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) to obtain the
specific sequence type (ST).
Statistical analysis
Data were analysed using Stata 11 (StataCorp LP, Texas,
USA). Univariate analysis was performed, and differences
in proportions of categorical variables were compared
using Pearson‘s χ2-test. The normality of continuous vari-
ables was assessed and the mean/median was reported
and compared using Student’s t-test/Wilcoxon-Mann–
Whitney test as appropriate. 95% confidence intervals (CI)
for colonization rates were calculated using the Wilsonscore. A stepwise backward multivariate logistic regression
was carried out to identify potential risk factors for
colonization. Variables identified in the univariate analysis
to be significantly associated with becoming colonized as
well as variables with a p-value <0.1 in the stepwise back-
ward approach were included in the final regression
model.
Results
Overall, 226 participants were enrolled, of whom 190
provided a pre- and post-travel faecal sample. Of these,
eleven participants were excluded because they travelled
to more than one of the above-mentioned countries. Of
the remaining 179 participants, 170 (95.0%) had a nega-
tive pre-travel screening for ESBL-Ent, five (2.8%) had a
positive screening and pre-travel data was missing for
four participants (2.2%). Thus, the analysis is based on
the data from 170 participants with a negative pre-travel
screening.
Overall, 68 travellers went to India, 49 to Sri Lanka, 39
to Nepal and 14 to Bhutan. Median age was 41 years
(range: 1–73 years), mean length of stay was 18.4 days
(range: 5–35 days, standard deviation (SD): 6.5 days).
Seventy-five travellers (44.1%) were male. Only 7 travel-
lers (4.6%) took antibiotics while travelling (missing data
regarding antibiotic use for 16 travellers, 12 of whom be-
came colonized). Of these, 5 (71.4%) became colonized
compared to 101 (68.7%) travellers not using any anti-
biotics (p = 0.879). The baseline characteristics and
demographic data are shown in Table 1.
After return, the overall colonization rate with ESBL-
Ent was 69.4% (95% CI 62.1-75.9%). The highest rate
was found in travellers returning from India (86.8%;
95% CI 78.5-95.0%) and the lowest in travellers return-
ing from Sri Lanka (34.7%; 95% CI 22.9-48.7%). Rates
for Nepal and Bhutan were 79.5% (95% CI 64.5-89.2%)
and 78.6% (95% CI 52.4-92.4%), respectively. The co-
lonization rates for India, Nepal, and Bhutan were sig-
nificantly higher than the one for Sri Lanka (p < 0.001).
ESBL-Ec were found in all of the colonized travellers,
but three had an additional ESBL-producing Klebsiella
pneumoniae and one an ESBL-producing Citrobacter
freundii. One traveller returning from India was colonized
with a carbapenemase-producing E. coli (confirmed by PCR
and sequencing as New Delhi metallo-beta-lactamase-1,
NDM-1).
The main risk factors for becoming colonized iden-
tified in the univariate analysis, besides travel destin-
ation, were reason for travelling (visiting friends and
relatives as compared to tourists) and consumption of
ice cream and pastry (Table 1).
In the multivariate logistic regression analysis, tra-
velling to India, Bhutan, or Nepal (as compared to
travelling to Sri Lanka), visiting friends and relatives
Table 1 Demographic data and travel associated risk factors analysed
Totala Neg-to-Posa,b Neg-to-Nega,c p-valued
Travellers 170 (100.0) 118 (69.4) 52 (30.6)
Destination India 68 (40.0) 59 (86.8) 9 (13.2)
<0.001
Bhutan 14 (8.2) 11 (78.6) 3 (21.4)
Nepal 39 (22.9) 31 (79.5) 8 (20.5)
Sri Lanka 49 (28.9) 17 (34.7) 32 (65.3)
Age (yrs, median, IQR) 41 (30–53) 41 (30–53) 40 (29–52) 0.899
Sex Female 95 (55.9) 66 (55.9) 29 (55.8)
0.984
Male 75 (44.1) 52 (44.1) 23 (44.2)
Length of stay < 2 weeks 34 (20.0) 21 (61.8) 13 (38.2)
0.5482-3 weeks 75 (44.1) 53 (70.7) 22 (29.3)
> 3 weeks 61 (35.9) 44 (72.1) 17 (27.9)
Weight (kg, median, IQR) 70 (58–78) 70 (59–78) 70 (57–78) 0.685
Travel Reason Tourist 115 (67.7) 73 (61.9) 42 (80.8)
0.047Business 23 (13.5) 18 (15.3) 5 (9.6)
VFR 32 (18.8) 27 (22.9) 5 (9.6)
Sleeping Place Hotel 81 (48.2) 56 (48.3) 25 (48.1)
0.298
Guest House 62 (36.9) 40 (34.5) 22 (42.3)
Private Household 17 (10.1) 15 (12.9) 2 (3.9)
Other 8 (4.8) 5 (4.3) 3 (5.7)
Eating Place Restaurant 135 (81.3) 94 (81.7) 41 (80.4)
0.837
Private 31 (18.7) 21 (18.3) 10 (19.6)
Daily Alcohol No 126 (74.1) 90 (76.3) 36 (69.2)
0.334
Yes 44 (25.9) 28 (23.7) 16 (30.8)
Tap Water Consumption No 101 (59.4) 77 (65.2) 24 (46.2)
0.019
Yes 69 (40.6) 41 (34.8) 28 (53.8)
Dairy Products No 21 (12.3) 11 (9.3) 10 (19.2)
0.070
Yes 149 (87.7) 107 (90.7) 42 (80.8)
Fruits No 144 (85.7) 99 (84.6) 45 (88.2)
0.538
Yes 24 (14.3) 18 (15.4) 6 (11.8)
Salad No 70 (41.4) 53 (45.3) 17 (32.7)
0.125
Yes 99 (58.6) 64 (54.7) 35 (67.3)
Ice Cream and Pastry No 78 (45.9) 48 (40.7) 30 (57.7)
0.040
Yes 92 (54.1) 70 (59.3) 22 (42.3)
Meat No 33 (19.4) 27 (81.8) 6 (18.2)
0.085
Yes 137 (80.6) 91 (66.4) 46 (33.6)
Travellers’ Diarrhoea No 106 (62.7) 70 (59.3) 36 (70.6)
0.164
Yes 63 (37.3) 48 (40.7) 15 (29.4)
PPI No 164 (96.5) 114 (96.6) 50 (96.1)
0.882
Yes 6 (3.5) 4 (3.4) 2 (3.9)
Note. IQR, interquartile range; PPI, proton pump inhibitor; VFR, visiting friends and relatives.
aData are presented as numbers and (%) if not otherwise indicated.
bNeg-to-Pos, people non-colonized before the trip and colonized with ESBL-Ent immediately after they return.
cNeg-to-Neg, people non-colonized before and after the trip to South Asia.
dDerived by Pearson’s Χ2-test or Student’s t-test/Wilcoxon-Mann–Whitney test.
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of ice cream and pastry, as well as length of stay
showed a significant association with becoming colo-
nized with ESBL-Ent. Drinking tap water was asso-
ciated with a decreased risk (Table 2).Table 2 Travel-associated risk factors for colonization: univar
OR (95% CI)
Destination India 1
Bhutan 0.56 (0.13-2.40
Nepal 0.59 (0.21-1.68
Sri Lanka 0.08 (0.03-0.20
Age 1.00 (0.98-1.02
Sex Female 1.00
Male 0.99 (0.52-1.92
Length of Stay (per week) 1.26 (0.88-1.80
Weight 1.01 (0.99-1.03
Travel Reason Tourist 1
Business 2.07 (0.72-5.98
VFR 3.11 (1.11-8.68
Sleeping Place Hotel 1
Guest House 0.81 (0.40-1.64
Private Household 3.35 (0.71-15.7
Other 0.74 (0.16-3.36
Eating Place Restaurant 1
Private 0.92 (0.40-2.12
Daily Alcohol No 1
Yes 0.70 (0.34-1.45
Tap Water Consumption No 1
Yes 0.52 (0.21-1.28
Dairy Products No 1
Yes 2.32 (0.92-5.86
Fruits No 1
Yes 1.36 (0.51-3.67
Salad No 1
Yes 0.59 (0.30-1.16
Ice Cream and Pastry No 1
Yes 1.99 (1.03-3.85
Meat No 1
Yes 0.44 (0.17-1.14
Travellers’ Diarrhoea No 1
Yes 1.65 (0.81-3.33
PPI No 1
Yes 0.88 (0.16-4.95
Note: OR, odds ratio; CI, confidence interval.
aderived by Wald test.
badjusted for the other covariates.Isolates and phenotypic characteristics
One-hundred-fifty-seven ESBL-Ec isolates (from 118
colonized travellers), detected at the first sampling after
the trip, were analysed. The overall antimicrobial sus-
ceptibility results are shown in Table 3. Notably, onlyiate and multivariate logistic regression model
p-valuea adjusted ORb (95% CI) p-valuea
1
) 0.434 0.66 (0.13-3.30) 0.615
) 0.325 0.57 (0.17-1.88) 0.355
) < 0.001 0.05 (0.02-0.16) < 0.001
) 0.722
) 0.984
) 0.215 2.08 0.010
) 0.416
1
) 0.179 1.58 (0.44-5.71) 0.483
) 0.031 3.86 (1.02-14.59) 0.046
) 0.560
6) 0.126
) 0.701
) 0.837
) 0.335
1
) 0.154 0.27 (0.08-0.87) 0.029
) 0.076
) 0.539
) 0.126
1
) 0.042 3.90 (1.61-9.43) 0.002
) 0.091
) 0.166
) 0.880
Table 3 Prevalence of ESBL-Ec sensitive to additional antibiotics for each country visiteda
All countries (n = 157) India (n = 82) Bhutan (n = 15) Nepal (n = 41) Sri Lanka (n = 19)
AMC 58.6 59.8 73.3 56.1 47.4
PIP-TAZ 96.8 95.1 100.0 95.1 100.0
CEP 35.0 46.3 26.7 24.4 15.8
MEM 100.0 100.0 100.0 100.0 100.0
SXT 51.0 48.8 73.3 51.2 42.1
CIP 59.2 47.6 86.7 70.7 63.2
NF 98.1 98.8 93.3 97.6 100.0
FOS 99.4 100.0 100.0 97.6 100.0
AMK 95.5 96.3 100.0 95.1 89.5
TOB 82.2 76.8 100.0 87.8 79.0
COL 100.0 100.0 100.0 100.0 100.0
Note: AMC, amoxicillin-clavulanate; PIP-TAZ, piperacillin-tazobactam; CEP, cefepime; MEM, meropenem; SXT, thrimetoprim-sulfamethoxazole; CIP, ciprofloxacin;
NF, nitrofurantoin; FOS, fosfomycin; AMK, amikacin; TOB, tobramycin; COL, colistin.
astated as %.
Kuenzli et al. BMC Infectious Diseases 2014, 14:528 Page 6 of 10
http://www.biomedcentral.com/1471-2334/14/528one isolate resistant to carbapenems was found. The sen-
sitivity rate to ciprofloxacin was lowest in India (47.6%,
95% CI 37.1-58.2), whereas the lowest sensitivities to
trimethoprim-sulfamethoxazon were in Sri Lanka (42.1%,
95% CI 23.1-63.7). Resistance rates against the other anti-
biotics tested were similar in all countries.
Molecular characteristics of the ESBL-Ec
As shown in Figure 1, rep-PCR indicated that most of
the E. coli isolates found in this study were sporadic and
not clonally related. Only three pandemic strains (i.e.,
ST131 and ST648) were found and the predominant
ESBL was the CTX-M-15. Neither a country-specific
E. coli strain nor a country-specific ESBL was observed.
Discussion
Colonization and infections with ESBL-Ent have been
described to be associated with recent travelling
[3,8-13,18-20,26]. Depending on the region visited,
colonization rates of over 70% have been recorded
[8,9,11,12]. In the current study, the highest colonization
rates with ESBL-Ec were found in travellers returning
from India, Nepal, and Bhutan. The figures are similar to
those previously described in studies investigating asymp-
tomatic travellers [8,9,11,12], but considerably higher than
the ones recorded in a recent Spanish study investigating
travellers’ diarrhoea after returning from tropical and sub-
tropical areas [13]. For a summary of existing prospective
studies see Table 4.
The rates observed in travellers returning from India,
Nepal, and Bhutan, are in contrast to the significantly
lower rate in travellers to the neighbouring country Sri
Lanka. The reasons for these differences remain unclear.
Differences in local prevalence are the most probable
reason, but respective data is almost non-existent.Studies looking at clinical isolates from India showed
rates of ESBL-Ec of 50-70% [27,28]. In Nepal, 13.5% of
E. coli and 16.5% of K. pneumoniae from urinary isolates
were found to be ESBL producers [29]. In Sri Lanka,
52.1% of E. coli from clinical isolates were ESBL pro-
ducers [30]. Regarding colonization with ESBL-Ec, one
study from India found a rate of 15.4% in pregnant
women [31]. However, no comparable data on carriage
in the community for the other countries exists.
In this study, participants who visited friends and rela-
tives showed a higher risk for becoming colonized than
participants travelling as tourists only. As human-to-
human transmission of ESBL-Ent is recorded [25], this
observation supports the possible association between
local prevalence and the risk for becoming colonized
while travelling.
Similarly, a difference in the local occurrence of ESBL-
Ent in the environment, in animals, and in food products
might explain the different colonization rates in travellers.
However, while studies on ESBL-Ent in the environment
do exist [32], data for South Asia is scant. Studies on
NDM-producing Enterobacteriaceae exist for India but
there are no similar studies for the other countries [21].
Nevertheless, the fact that the E. coli strains found in
this study are mostly of low-virulence STs (e.g., ST10
and ST10 complex) indicating a possible link with food,
food-producing animals, and/or environment and not
primarily “human” strains (e.g., ST131 and ST648) sup-
ports the hypothesis of an environmental origin of the
colonization [33,34].
Besides travel destination, consumption of ice cream
and pastry was associated with becoming colonized in this
study. Transmission of ESBL-Ent via the food chain has
been described [6,7], and as both ice cream and pastry
contain animal products, such an association is plausible.
Figure 1 Molecular characteristics of the 80 representative ESBL-producing isolates according to rep-PCR and multi locus sequencing.
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taminated during preparation or storage as they both are
not heated again before consumption.
According to our analysis, drinking tap water is not
associated with becoming colonized. This is completely
contradictory to other studies which have found NDM-
1-producing bacteria in the drinking water of New
Delhi [21]. However, a previous study by Kennedy et al.
has shown a negative association between drinking tap
water and becoming colonized with resistant E. coli as
well [9]. As in our study, no clear explanation for thisseemingly counterintuitive result was found. Possibly,
this observation is explained by drinking tap-water being a
proxy for a certain way of travelling which protects against
becoming colonized (i.e. hotels with chemically treated
water). The fact that neither sleeping place nor eating place
was associated with an increased risk for colonization could
be explained by a lack of statistical power.
Increased length of stay as a risk factor for becoming
colonized is self-explanatory. In contrast to previous stud-
ies [8,9,12,18], suffering from gastrointestinal symptoms
while travelling was not a risk factor for colonization.
Table 4 Prospective studies on travel-associated colonization with ESBL-producing Enterobacteriaceae – rates and risk
factors
Travellers
(n) overall
Colonization
rate (%) overall
Travellers (n) India/
Indian subcontinent
Colonization rate (%) India/
Indian subcontinent
Risk factors*
Current study 170 69.4 68 86.8 Travel Destination
Length of Stay
Visiting Friends and Relatives
Consumption of Ice Cream &
Pastry
Tängden et al. [8] 100 24.0 8 88.0 Travelling to India
Gastroenteritis during Trip
Kennedy et al. [9]a 102 21.6 14 57.1 Gastroenteritis during Trip
Antibiotics while Travelling
Weisenberg et al. [10] 28 25.0 7b 28.6 not done
Paltansing et al. [11] 370 30.5 25c 73.0c Travelling to South and East Asia
Östholm-Balkhed et al. [12] 226 30.0 14 71.4 Travelling to Indian subcontinent,
Asia, Africa north of equator
Age
Gastroenteritis during Trip
*Risk factors for becoming colonized for all the countries included in the respective study.
arisk factor for colonization with E. coli resistant to gentamicin, ciprofloxacin and/or third-generation cephalosporins.
bSouth Asia (not specified).
cSouth Asia: Bangladesh, India, Maldives, Nepal and Sri Lanka.
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sociated with becoming colonized [9], was only reported
by 7 travellers in our study.
By focusing on the Indian subcontinent, risk factors not
previously described could be identified. However, given
the colonization rate of almost 90% in travellers returning
from India, the relevance of single risk factors is im-
possible to dissect. The search for risk factors in such a
highly-endemic setting seems futile because colonization
most likely originates from ubiquitous sources. This is
supported by the fact that the E. coli isolates determined
in the rep-PCR were mainly sporadic and less clonally re-
lated and that the MLST showed non-pandemic STs. The
lack of clonal relatedness in ESBL-Ec acquired while tra-
velling further supports the idea of various origins.
When looking at the high colonization rates with
ESBL-Ent found in this study, the question about
carbapenem-resistance arises for two reasons. Firstly, as a
clear association between symptomatic infections with
ESBL-Ent and recent travelling has been recorded [33],
knowledge of high colonization rates in travellers might
lead to an increase in the use of carbapenems, facilitating
resistance development. More so, as almost 50% of the
ESBL-Ec in this study were resistant or had intermediate
resistance against trimethoprim-sulfamethoxazole or cip-
rofloxacin, mirroring the high additional resistance rates
found in other studies [8,11,12,19,20]. Secondly, South
Asia not only has high rates of ESBL-Ent but serves as
an reservoir for NDM-1-Ent [16] as well. To date,colonization and infection with Carb-Ent occurs mainly in
travellers with exposure to healthcare facilities [16] but
has been described sporadically in healthy travellers as
well [35]. Moreover, with NDM-1 already occurring in the
environment [21], it might only be a question of time until
Carb-Ent will be imported in significant numbers to low-
endemicity regions through travellers as well.
Our study has several strengths and limitations. By fo-
cusing on the Indian sub-continent, we were able to iden-
tify new potential risk factors associated with becoming
colonized. Additionally, by performing a molecular cha-
racterization of the detected strains, more information on
the epidemiology of ESBL-producing Enterobacteriaceae
in the respective countries could be gained. However, by
only looking at a limited number of travel destinations,
the results obtained are not generalizable to other travel
destinations. On a technical level, colonization with mul-
tiple strains might not always have been detected and
colonization below detection level cannot be excluded.
Conclusions
Looking at the high colonization rates in travellers to the
Indian subcontinent and the microbiological findings of
mostly sporadic strains, the source of colonization most
likely is ubiquitous (e.g. environment, food). Therefore,
avoidance of colonization while travelling seems impos-
sible, at least in highly-endemic areas. As a consequence,
travel-related spread from high to low-endemicity areas
will probably further increase in the future as the local
Kuenzli et al. BMC Infectious Diseases 2014, 14:528 Page 9 of 10
http://www.biomedcentral.com/1471-2334/14/528prevalence in many regions of the world changes. As a
clinical consequence, recent travel history of patients
showing signs of infection should be taken into account
when deciding on an empirical antibiotic treatment.
Moreover, in the future, the travel-related spread of
carbapenemase-producing Enterobacteriaceae needs to be
closely monitored in order to detect when colonization
with Carb-Ent in travellers starts to increase substantially.
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